Telehealth Companies Face Revenue Decline as In-Person Care Returns

The pandemic boom that sent telehealth stocks soaring is officially over. Companies that once boasted triple-digit growth rates are now reporting revenue declines as patients return to doctors’ offices and virtual care normalizes into a smaller slice of healthcare delivery.

Teladoc Health, the sector’s biggest player, recently posted its first quarterly revenue decline since going public, dropping 3% year-over-year. The company’s stock has plummeted over 90% from its 2021 peak of $308 per share. Other major telehealth providers are facing similar headwinds as the industry grapples with a fundamental shift in patient behavior and investor expectations.

The Great Telehealth Correction

The numbers tell a stark story of an industry in transition. Amwell reported a 16% revenue decline in its most recent quarter, while Doxy.me saw user engagement drop by nearly 40% compared to peak pandemic levels. Even specialty platforms focused on mental health and chronic disease management are struggling to maintain the explosive growth they experienced when lockdowns made virtual care a necessity rather than a convenience.

The correction goes beyond just revenue. Telehealth companies are slashing workforce numbers to match demand. Babylon Health, once valued at over $2 billion, filed for bankruptcy in 2023. MDLive, acquired by Cigna for $2.7 billion at the height of the pandemic, has undergone significant restructuring as parent company Evernorth adjusts expectations.

Investment dollars have dried up accordingly. Venture capital funding for telehealth startups dropped 67% in 2023 compared to 2021, according to Rock Health data. The sector raised just $2.8 billion last year, down from $8.4 billion two years earlier. This funding drought is forcing companies to focus on profitability rather than growth at all costs.

The regulatory environment has also shifted. Emergency pandemic provisions that allowed cross-state telehealth practice and relaxed prescription rules are being rolled back. The Drug Enforcement Administration has tightened controls on remote prescribing of controlled substances, particularly impacting mental health platforms that relied heavily on prescribing antidepressants and anxiety medications.

Patient Preferences Drive Market Reality

Consumer behavior data reveals why telehealth companies are struggling. While virtual visits peaked at 38 times pre-pandemic levels in April 2020, they’ve since stabilized at just 2-3 times baseline levels. Patients consistently report preferring in-person care for complex conditions, routine check-ups, and procedures requiring physical examination.

Insurance reimbursement rates for telehealth visits have also returned to pre-pandemic levels in many states, making virtual consultations less financially attractive for both providers and patients. Copays for telehealth visits now often match in-person visits, eliminating a key cost advantage that drove adoption.

The competition landscape has intensified as traditional healthcare systems launched their own telehealth platforms. Major hospital networks like Mayo Clinic, Cleveland Clinic, and Kaiser Permanente now offer comprehensive virtual care options, keeping patients within their existing healthcare ecosystems rather than driving them to standalone telehealth companies.

Primary care physicians have also adapted, integrating limited telehealth capabilities into their practices for follow-up visits and routine consultations. This hybrid model captures much of the convenience factor that made pure-play telehealth companies attractive without requiring patients to establish new provider relationships.

Survivors Focus on Niche Markets

Companies that are weathering the downturn successfully have pivoted to specialized niches rather than competing in general primary care. Mental health-focused platforms like BetterHelp and Talkspace continue showing growth, though at more modest rates than during peak pandemic anxiety periods.

Chronic disease management remains a bright spot, with companies serving diabetes, hypertension, and heart disease patients maintaining steady user bases. These conditions require ongoing monitoring and medication adjustments that translate well to virtual care models. Remote patient monitoring technology, including connected devices and wearables, creates additional revenue streams beyond consultation fees.

Some telehealth companies are pursuing B2B partnerships with employers and health plans rather than direct consumer models. This approach provides more predictable revenue streams and higher reimbursement rates. Walmart, Amazon, and other retailers entering healthcare are partnering with telehealth providers to offer services within their broader health and wellness strategies.

The enterprise market offers more stability than consumer-facing platforms. Companies providing telehealth infrastructure to hospitals and medical practices, rather than competing with them, are finding sustainable business models. This includes software platforms, integration services, and white-label solutions that healthcare systems can brand as their own.

Industry Consolidation Accelerates

Merger and acquisition activity is picking up as stronger players acquire struggling competitors at significant discounts. Teladoc’s acquisition of Livongo for $18.5 billion in 2020 now looks prescient, giving the company a foothold in chronic disease management before the general telehealth market contracted.

The consolidation mirrors patterns seen in other pandemic-boom industries. Just as subscription box companies face declining customer retention as consumers return to pre-pandemic shopping habits, telehealth providers must find sustainable niches beyond crisis-driven demand.

Smaller telehealth startups are being acquired by healthcare technology companies, pharmacy chains, and health insurers looking to integrate virtual care capabilities. CVS Health, Walgreens, and other pharmacy retailers are particularly active acquirers, viewing telehealth as complementary to their expanded healthcare services.

International expansion offers another path forward for US-based companies, particularly in markets where healthcare infrastructure remains limited. Several telehealth providers are exploring partnerships in Latin America, Southeast Asia, and Africa, where regulatory barriers may be lower and demand for virtual care more sustained.

Looking ahead, industry analysts expect telehealth to stabilize at roughly 10-15% of total healthcare encounters, significantly higher than pre-pandemic levels but far below peak crisis usage. Companies that can adapt to this new normal while finding profitable niches will survive the current shakeout. Those still chasing pandemic-era growth metrics face an increasingly difficult road ahead.

The telehealth revolution isn’t over, but it’s certainly different than investors expected three years ago. As the dust settles, a smaller but more sustainable industry is emerging from the pandemic boom and bust cycle.